Problem antibiotske rezistencije kod lečenja Helicobacter pylori infekcije

Vladimir Milivojević

doi:10.5937/mp74-41665

Vladimir Milivojević

DOI: https://doi.org/10.5937/mp74-41665

Ključne reči: Helicobacter pylori infection, antibiotic resistance, tailored made therapy

Sažetak

Pravovremeno i adekvatno lečenje Helicobacter pylori (H. pylori) infekcije od suštinskog je značaja imajući u vidu visoku stopu prevalencije (>50%), činjenicu da infekcija ovim patogenom izaziva hronični gastritis kao i značajne komplikacije u vidu ulkusne bolesti, MALT limfoma, metaplazije i adenokarcinoma želuca. Brojne nacionalne preporuke i internacionalni vodiči diktiraju efikasnost terapije, ali njihiovo nekonzistentno sprovođenje remeti stopu izlečenja i povećava mogućnost razvoja antibiotske rezistencije. Prema preliminarnim podacima stopa rezistencije u Srbiji je visoka. Cilj terapijskih vodiča treba da bude efiksana terapija, koja je bezbedna i koja ako je moguće prevenira rastuću rezistenciju na antibiotike. Nove dijagnostičke tehnike poput bakterijske kulture i PCR mogu olakšati dijagnostiku i utvrditi antibiotsku rezistenciju što dalje dovodi do moguće primene individualizovanog terapijskog režima koji upravo može omogućiti bolju stopu izlečenja prevenirajući dalju antibiotsku rezistenciju.

Reference

LITERATURA:

1. Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 2017; 153: 420–429.

2. Nyssen OP, Bordin D, Tepes B On behalf of the Hp-EuReg Investigators, et al. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut. 2021;70:40-54.

3. Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 2016; 43: 514–533.

4. Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34–42

5. Bujanda L, Nyssen OP, Vaira D, Saracino IM, Fiorini G, Lerang F, et al. Antibiotic Resistance Prevalence and Trends in Patients Infected with Helicobacter pylori in the Period 2013-2020: Results of the European Registry on H. pylori Management (Hp-EuReg). Antibiotics (Basel). 2021 Sep 1;10(9).

6. Megraud F, Bruyndonckx R, Coenen S, et al. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut 2021;70:1815–1822

7. Milivojevic V, Kekic D, Ranin L, Medic B, et al. Primary and secondary Helicobater pylori resistance among Serbian adult pupaltion. Helicobacter, 2019 1 (Vol. 24). Kaunas, September 2019.

8. Savoldi, A.; Carrara, E.; Graham, D.Y.; Conti, M.; Tacconelli, E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology 2018, 155, 1372–1382.e17.

9. Milivojevic V, Milosavljevic T. Review –Treatment of Helicobacter pylori infection. Microb Health Dis 2021; 3: e525

10. Mascellino MT, Porowska B, De Angelis M, et al. Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection. Drug Des Dev Ther 2017; 11: 2209–2220.

11. Arslan N, Yilmaz O and Demiray-Gurbuz E. Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection. World J Gastroenterol 2017; 23: 2854–2869

12. Ierardi E, Giorgio F, Iannone A, et al. Noninvasive molecular analysis of Helicobacter pylori: is it time for tailored first-line therapy? World J Gastroenterol 2017; 23: 2453–2458.

13. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017; 66: 6–30.

14. Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut 2022;71:1724–1762.

15. Wenzhen Y, Yumin L, Quanlin G, et al. Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials. Intern Med 2010; 49: 1103–1109.

16. Chen H, Dang Y, Zhou X, et al. Tailored therapy versus empiric chosen treatment for Helicobacter pylori eradication: a meta-analysis. Medicine (Baltimore) 2016; 95: e2750.

17. Espada M, Nyssen OP and Gisbert JP. Empirical versus susceptibility-guided treatment of Helicobacter pylori infection: a meta-analysis. Helicobacter 2020; 25(Suppl. 1): 26.

18. Huang HT, Wang HM, Yang SC, et al. Efficacy of a 14-day quadruple-therapy regimen for thirdline Helicobacter pylori eradication. Infect Drug Resist 2018; 11: 2073–2080.

19. Cammarota G, Ianiro G, Bibbo S, et al. Cultureguided treatment approach for Helicobacter pylori infection: review of the literature. World J Gastroenterol 2014; 20: 5205–5211.